journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Heart Failure

journal
https://www.readbyqxmd.com/read/28436136/effects-of-ferric-carboxymaltose-on-hospitalisations-and-mortality-rates-in-iron-deficient-heart-failure-patients-an-individual-patient-data-meta-analysis
#1
Stefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, Gerasimos Filippatos, Josep Comin-Colet, Frank Ruschitzka, Thomas F Lüscher, Gregory P Arutyunov, Michael Motro, Claudio Mori, Bernard Roubert, Stuart J Pocock, Piotr Ponikowski
AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v. ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on recurrent hospitalisations and mortality in HF patients with ID...
April 24, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28425168/right-ventricular-failure-after-left-ventricular-assist-device-implant-towards-finding-common-ground
#2
EDITORIAL
Jorge Silva Enciso, Barry Greenberg
No abstract text is available yet for this article.
April 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28425164/the-fallacy-of-resting-echocardiographic-parameters-of-cardiac-function-in-heart-failure-with-preserved-ejection-fraction-add-global-longitudinal-strain-to-the-list
#3
EDITORIAL
Dragoş Vinereanu, Andrei D Mǎrgulescu
No abstract text is available yet for this article.
April 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28401618/tailoring-mineralocorticoid-receptor-antagonist-therapy-in-heart-failure-patients-are-we-moving-towards-a-personalized-approach
#4
REVIEW
João Pedro Ferreira, Robert J Mentz, Anne Pizard, Bertram Pitt, Faiez Zannad
The aim of personalized medicine is to offer a tailored approach to each patient in order to provide the most effective therapy, while reducing risks and side effects. The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated major benefits in heart failure with reduced ejection fraction (HFrEF), results with challenging inconsistencies in heart failure with preserved ejection fraction (HFpEF), and 'neutral' preliminary results in acute heart failure. Data derived from landmark trials are generally applied in a 'one size fits all' manner and the development and implementation of more personalized MRA management would offer the potential to improve outcomes and reduce side effects...
April 12, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28393439/effect-of-intracoronary-administration-of-aav1-serca2a-on-ventricular-remodelling-in-patients-with-advanced-systolic-heart-failure-results-from-the-agent-hf-randomized-phase-2-trial
#5
Jean-Sébastien Hulot, Joe-Elie Salem, Alban Redheuil, Jean-Philippe Collet, Shaida Varnous, Patrick Jourdain, Damien Logeart, Estelle Gandjbakhch, Claude Bernard, Stéphane N Hatem, Richard Isnard, Philippe Cluzel, Claude Le Feuvre, Pascal Leprince, Nadjib Hammoudi, François M Lemoine, David Klatzmann, Eric Vicaut, Michel Komajda, Gilles Montalescot, Anne-Marie Lompré, Roger J Hajjar
AIMS: Restoration of sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA2a) activity through gene transfer improved cardiac function in experimental and pilot studies in humans with heart failure. The AGENT-HF (NCT01966887) trial investigated the impact of adeno-associated virus (AAV1)/SERCA2a on ventricular remodelling using multimodality non-invasive cardiac imaging. METHODS AND RESULTS: AGENT-HF was a single centre, randomized, double-blind, placebo-controlled trial in adult patients with NYHA class III-IV ischaemic or non-ischaemic heart failure and left ventricular ejection fraction ≤35%...
April 10, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28387033/non-invasive-measurement-of-right-atrial-pressure-by-near-infrared-spectroscopy-preliminary-experience-a-report-from-the-sica-hf-study
#6
Pierpaolo Pellicori, Andrew L Clark, Anna Kallvikbacka-Bennett, Jufen Zhang, Alessia Urbinati, Luca Monzo, Riet Dierckx, Stefan D Anker, John G F Cleland
AIMS: To assess the clinical value of measuring right atrial pressure (RAP) using near-infrared spectroscopy (NIRS) in patients with chronic heart failure (CHF). METHODS AND RESULTS: RAP was measured non-invasively using NIRS over the external jugular vein (Venus 1000, Mespere LifeSciences, Canada) in ambulatory patients with CHF enrolled in the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) programme. Comparing 243 patients with CHF (mean age 71 years; mean left ventricular ejection fraction (LVEF) 45%, median NT-proBNP 788 ng/L) to 49 controls (NT-proBNP ≤125 ng/L), RAP was 7 [interquartile range (IQR) 4-11] mmHg vs...
April 6, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28387002/recovered-heart-failure-with-reduced-ejection-fraction-and-outcomes-a-prospective-study
#7
Josep Lupón, Carles Díez-López, Marta de Antonio, Mar Domingo, Elisabet Zamora, Pedro Moliner, Beatriz González, Javier Santesmases, Maria I Troya, Antoni Bayes-Genis
AIMS: Significant recovery of left ventricular ejection fraction (LVEF) occurs in a proportion of patients with heart failure (HF) and reduced ejection fraction (HFrEF). We analysed outcomes, including mortality [all-cause, cardiovascular (CV), HF-related, and sudden death], and HF-related hospitalizations in this HF-recovered group. The primary endpoint was a composite of CV death or HF hospitalization. METHODS AND RESULTS: LVEF was assessed at baseline and at 1 year in 1057 consecutive HF patients...
April 6, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28386917/epidemiology-and-one-year-outcomes-in-patients-with-chronic-heart-failure-and-preserved-mid-range-and-reduced-ejection-fraction-an-analysis-of-the-esc-heart-failure-long-term-registry
#8
Ovidiu Chioncel, Mitja Lainscak, Petar M Seferovic, Stefan D Anker, Maria G Crespo-Leiro, Veli-Pekka Harjola, John Parissis, Cecile Laroche, Massimo Francesco Piepoli, Candida Fonseca, Alexandre Mebazaa, Lars Lund, Giuseppe A Ambrosio, Andrew J Coats, Roberto Ferrari, Frank Ruschitzka, Aldo P Maggioni, Gerasimos Filippatos
AIMS: The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors for mortality at 1 year in each group. METHODS AND RESULTS: The European Society of Cardiology Heart Failure Long-Term Registry is a prospective, observational study collecting epidemiological information and 1-year follow-up data in 9134 HF patients. Patients were classified according to baseline LVEF into HF with reduced EF [EF <40% (HFrEF)], mid-range EF [EF 40-50% (HFmrEF)] and preserved EF [EF >50% (HFpEF)]...
April 6, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28386910/iron-deficiency-and-red-cell-indices-in-patients-with-heart-failure
#9
Michał Tkaczyszyn, Josep Comín-Colet, Adriaan A Voors, Dirk J van Veldhuisen, Cristina Enjuanes, Pedro Moliner-Borja, Piotr Rozentryt, Lech Poloński, Waldemar Banasiak, Piotr Ponikowski, Peter van der Meer, Ewa A Jankowska
AIMS: To investigate the prevalence of iron deficiency (ID) in heart failure (HF) patients with normal vs. abnormal red cell indices (RCI), the associations between iron parameters and RCI, and prognostic consequences of ID independently of RCI. METHODS AND RESULTS: We analysed clinical data of 1821 patients with HF [mean age 66 ± 13 years; 71% men; New York Heart Association class I/II/III/IV (11%/39%/44%/6%); left ventricular ejection fraction >45%: 19%]. Iron deficiency (ferritin <100 µg/L or ferritin 100-299 µg/L with transferrin saturation <20%) was common irrespective of the presence of anaemia (haemoglobin <12 g/dL in women and <13 g/dL in men) or low RCI, from 75% in anaemic subjects with low mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), and MCH concentration (MCHC), to 36% in non-anaemic subjects with MCV, MCH, and MCHC above the lower limit of normal...
April 6, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28370872/observations-on-the-blood-pressure-paradox-in-heart-failure
#10
EDITORIAL
Hector O Ventura, Franz H Messerli, Carl J Lavie
No abstract text is available yet for this article.
April 3, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28371221/prediction-of-right-ventricular-failure-after-ventricular-assist-device-implant-systematic-review-and-meta-analysis-of-observational-studies
#11
REVIEW
Diego Bellavia, Attilio Iacovoni, Cesare Scardulla, Lorenzo Moja, Michele Pilato, Sudhir S Kushwaha, Michele Senni, Francesco Clemenza, Valentina Agnese, Calogero Falletta, Giuseppe Romano, Joseph Maalouf, Michael Dandel
Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is associated with increased morbidity and mortality, but the identification of LVAD candidates at risk for RVF remains challenging. We undertook a systematic review and meta-analysis of observational studies of risk factors associated with RVF after LVAD implant. Thirty-six studies published between 1 January 1995 and 30 April 2015, comprising 995 RVF patients out of a pooled final population of 4428 patients, were identified...
March 31, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28371029/high-density-lipoprotein-associated-paraoxonase-1-a-possible-prognostic-biomarker-for-heart-failure
#12
EDITORIAL
Oren Rom, Michael Aviram
No abstract text is available yet for this article.
March 31, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28370906/myocardial-expression-of-toll-like-receptor-4-predicts-the-response-to-immunosuppressive-therapy-in-patients-with-virus-negative-chronic-inflammatory-cardiomyopathy
#13
Cristina Chimenti, Romina Verardo, Fernanda Scopelliti, Claudia Grande, Nicola Petrosillo, Pierluca Piselli, Ruggero De Paulis, Andrea Frustaci
AIMS: We sought to determine whether myocardial expression of Toll-like receptor 4 (TLR4) may predict the response to immunosuppression. METHODS AND RESULTS: Endomyocardial biopsies from 237 patients with virus-negative inflammatory cardiomyopathy treated with immunosuppression were retrospectively examined for the expression of TLR4, differentiating those patients responding to immunosuppression (n = 193) from non-responder patients (n = 44). A semiquantitative evaluation of the immunoreactivity (grading from 0 to 4) for TLR4 and human leucocyte antigen (HLA)-DR was performed together with real-time PCR and western blot for TLR4...
March 31, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28370829/characterization-of-heart-failure-patients-with-mid-range-left-ventricular-ejection-fraction-a-report-from-the-chart-2-study
#14
Kanako Tsuji, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Takeshi Yamauchi, Takeo Onose, Ruri Abe, Takuya Oikawa, Shintaro Kasahara, Masayuki Sato, Takashi Shiroto, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa
BACKGROUND: The new category of heart failure (HF), HF with mid-range left ventricular ejection fraction (LVEF) (HFmrEF), has recently been proposed. However, the clinical features of HFmrEF, with reference to HF with preserved LVEF (HFpEF) and HF with reduced LVEF (HFrEF) in the same HF cohort, remain to be fully examined. METHODS AND RESULTS: In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 Study, we examined 3480 consecutive HF patients with echocardiography data consisting of 2154 HFpEF (LVEF ≥50%), 596 HFmrEF (LVEF 40-49%) and 730 HFrEF (LVEF <40%)...
March 31, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28370822/the-complexity-of-diuretic-resistance
#15
EDITORIAL
Doron Aronson
No abstract text is available yet for this article.
March 31, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28371075/associations-with-and-prognostic-impact-of-chronic-kidney-disease-in-heart-failure-with-preserved-mid-range-and-reduced-ejection-fraction
#16
Ida Löfman, Karolina Szummer, Ulf Dahlström, Tomas Jernberg, Lars H Lund
AIMS: As the role of chronic kidney disease (CKD) in different types of heart failure (HF) is poorly understood, our aim was to compare CKD in HF with preserved (HFpEF), mid-range (HFmrEF), and reduced ejection fraction (HFrEF) with regard to prevalence, associations and prognostic role. METHODS AND RESULTS: Patients in the Swedish Heart Failure Registry were divided into three groups based on EF (≥50%, 40-49% and <40%). CKD was defined as an estimated glomerular filtration rate ≤60 mL/min...
March 29, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28370920/exercise-intolerance-in-heart-failure-with-preserved-ejection-fraction-time-to-scrutinize-diuretic-therapy
#17
David Montero, Andreas J Flammer
No abstract text is available yet for this article.
March 29, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28345302/outcome-of-subsequent-pregnancies-in-patients-with-a-history-of-peripartum-cardiomyopathy
#18
Denise Hilfiker-Kleiner, Arash Haghikia, David Masuko, Justus Nonhoff, Dominik Held, Elena Libhaber, Mark C Petrie, Niki L Walker, Edith Podewski, Dominik Berliner, Johann Bauersachs, Karen Sliwa
AIMS: Subsequent pregnancies (SSPs) in patients with peripartum cardiomyopathy (PPCM) have a high risk of heart failure relapse. We report on outcome of SSPs in PPCM patients in Germany, Scotland, and South Africa. METHODS AND RESULTS: Among 34 PPCM patients with a SSP, pregnancy ended prematurely in four patients while it was full-term in 30. Overall relapse rate [left ventricular ejection fraction, LVEF <50% or death after at least 6-month follow-up] was 56% with 12% (4/34) mortality...
March 27, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28345202/prognostic-value-of-long-term-blood-pressure-changes-in-patients-with-chronic-heart-failure
#19
Florian A Schmid, Oliver Schlager, Philipp Keller, Burkhardt Seifert, Ruizhu Huang, Georg M Fröhlich, Thomas F Lüscher, Frank Ruschitzka, Frank Enseleit
BACKGROUND: Chronic heart failure (CHF) is the final stage of many heart diseases. To improve outcomes, important risk factors for adverse clinical events in the CHF population need to be identified. The aim of the present study was to delineate the influence of long-term blood pressure (BP) changes on prognosis and mortality in a real-world cohort of CHF patients. METHODS AND RESULTS: This is a retrospective longitudinal analysis. Repeated office BP measurements were scheduled during follow-up visits every 3-6 months...
March 27, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28345190/new-medicinal-products-for-chronic-heart-failure-advances-in-clinical-trial-design-and-efficacy-assessment
#20
REVIEW
Martin R Cowie, Gerasimos S Filippatos, Maria de Los Angeles Alonso Garcia, Stefan D Anker, Anna Baczynska, Daniel M Bloomfield, Maria Borentain, Karsten Bruins Slot, Maureen Cronin, Pieter A Doevendans, Amany El-Gazayerly, Claudio Gimpelewicz, Narimon Honarpour, Salim Janmohamed, Heidi Janssen, Albert M Kim, Dominik Lautsch, Ian Laws, Martin Lefkowitz, Jose Lopez-Sendon, Alexander R Lyon, Fady I Malik, John J V McMurray, Marco Metra, Santiago Figueroa Perez, Marc A Pfeffer, Stuart J Pocock, Piotr Ponikowski, Krishna Prasad, Isabelle Richard-Lordereau, Lothar Roessig, Giuseppe M C Rosano, Warren Sherman, Wendy Gattis Stough, Karl Swedberg, Benoit Tyl, Faiez Zannad, Caroline Boulton, Pieter De Graeff
Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart failure patients is characterized by a reduction in life expectancy, a progressive decline in health-related quality of life and functional status, as well as a high risk of hospitalization. New approaches are needed to address the unmet medical needs of this patient population. The European Medicines Agency (EMA) is undertaking a revision of its Guideline on Clinical Investigation of Medicinal Products for the Treatment of Chronic Heart Failure...
March 27, 2017: European Journal of Heart Failure
journal
journal
34664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"